Carlisle Tara C, Bateman James R, Yang Yanghong, Lachner Christian, Stockbridge Melissa D, Flashman Laura A, Chemali Zeina, Alzbeidi Nasir, Pressman Peter S, Osibajo Anne-Marie, Bobrin Bradford D, Martinez-Menendez Carlos J, Teixeira Antonio L, Daffner Kirk R
Department of Neurology, Behavioral Neurology Section, University of Colorado School of Medicine, Aurora (Carlisle, Flashman); Department of Neurology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, N.C. (Bateman, Pressman); Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, and Department of Neurology, SUNY Downstate Health Sciences University, Brooklyn, New York City (Yang); Department of Neurology and Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, Fla. (Lachner); Department of Neurology, Cerebrovascular Division, Johns Hopkins University School of Medicine, Baltimore (Stockbridge); Department of Neurology, Harvard Medical School, Brigham and Women's Hospital, Boston (Chemali); Sakina Mental Health Services, SEHA, Abu Dhabi, United Arab Emirates (Alzbeidi); Department of Psychiatry, Atlantic Health System-Overlook Medical Center, Summit, N.J., and Department of Neurology, Icahn School of Medicine, Mount Sinai Hospital, New York City (Osibajo); Lower Merion Counseling Services, Lower Merion, Pa. (Bobrin); Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, and Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, Department of Neurology, University of Texas Health Science Center at San Antonio, San Antonio (Martinez-Menendez, Teixeira); Department of Neurology, Division of Cognitive and Behavioral Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston (Daffner).
J Neuropsychiatry Clin Neurosci. 2025 Jun 26:appineuropsych20240203. doi: 10.1176/appi.neuropsych.20240203.
Alzheimer's disease (AD) is a common neurodegenerative illness affecting nearly 7 million people in the United States. Until 2023, no disease-targeting pharmacotherapeutics were widely available outside of research studies. With relatively recent regulatory approval and increasing availability of antiamyloid therapies (AATs) in the United States, management of AD is rapidly shifting from symptomatic and supportive care alone to treatments aimed at disease modification. Appropriate selection of patients for AATs can be challenging and varies among health care settings and systems despite published appropriate-use recommendations. The first of this two-part Treatment in Behavioral Neurology & Neuropsychiatry series from the American Neuropsychiatric Association Dementia Special Interest Group addresses the challenges with patient selection. In this second part, the authors offer dementia-focused health care vignettes to illustrate challenges with AAT delivery encountered in different settings and discuss emerging logistical issues associated with delivery of dementia-focused care based on AAT protocols.
